Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors.
Accumulating data from patients treated with checkpoint inhibitors and other immunomodulatory agents indicate that harnessing the power of the immune system is integral to achieve improve long-term cancer containment rates and prolong patient survival. Due to their mechanism of action, immunotherapeutic approaches have the potential to be effective against almost every tumor type. Durable responses to immunotherapy and prolonged patient survival have indeed been documented in individuals with melanoma, as well as kidney and lung cancer. These advances call for the re-evaluation of how clinical benefit is measured in an era in which long-term tumor control and survival are achievable treatment goals.
Gustave Roussy Cancer Campus; Grand Paris; Villejuif, France.
Alexander
A
Eggermont
Gustave Roussy Cancer Campus; Grand Paris; Villejuif, France.
Caroline
C
Robert
Gustave Roussy Cancer Campus; Grand Paris; Villejuif, France.
Jean Charles
JC
Soria
Gustave Roussy Cancer Campus; Grand Paris; Villejuif, France.
Laurence
L
Zitvogel
checkpoint inhibitors; immunotherapy; melanoma; solid tumors; survival; ulceration